Explore the words cloud of the Proteasome in cancer project. It provides you a very rough idea of what is the project "Proteasome in cancer" about.
The following table provides information about the project.
INSTYTUT MEDYCYNY DOSWIADCZALNEJ I KLINICZNEJ IM MIROSLAWA MOSSAKOWSKIEGO POLSKIEJ AKADEMII NAUK
|Coordinator Country||Poland [PL]|
|Total cost||146˙462 €|
|EC max contribution||146˙462 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2018-05-01 to 2020-04-30|
Take a look of project's partnership.
|1||INSTYTUT MEDYCYNY DOSWIADCZALNEJ I KLINICZNEJ IM MIROSLAWA MOSSAKOWSKIEGO POLSKIEJ AKADEMII NAUK||PL (WARSZAWA)||coordinator||146˙462.00|
The 26S/20S proteasome and immunoproteasome machinery is the major protein degradation system in human cells and a strongly oncogenic factor upregulated in most human neoplasias of various tissues. Thus, it is a target of clinically approved treatment protocols in human multiple myeloma and mantle cell lymphoma. However, clinical trials have shown a limited effect of proteasome inhibitors in solid tumors and their metastases, despite initial encouraging results in vitro and in xenografts.
The main objective of the following project is to understand the oncogenic contribution of the human proteasome machinery to the proteome and transcriptome of human cancer cells and to use this knowledge to improve the anti-cancer therapeutic approaches targeting the proteasome and its downstream effectors, in human cancer types causing most deaths in the European Union – lung, colon/rectum and pancreatic cancers.
The main research hypothesis is that the unknown mechanisms downstream of the human proteasome machinery are critical for cancer progression and will be effective as drug targets in the treatment of the solid tumors and their metastasis. Discovering these mechanisms using proteome-scale mass spectrometry analysis combined with RNA-sequencing will allow in this project to: (i) identify novel proteasome targets and understand reprogramming of human neoplastic cells by the proteasome machinery on the basic level in multiple myeloma, lung, colon and pancreatic cancer cultured cells, (ii) understand the reason for the exceptionally efficient therapeutic effect of the proteasome inhibitor carfilzomib in multiple myeloma compared to solid tumor cancer cells, and (iii) test in frozen/fixed tumor material, cell cultures the functional validity of the discovered proteasome targets as therapeutic target candidates in lung, colon and pancreatic cancers – which could increase efficiency or bypass targeting of the proteasome machinery by carfilzomib in the solid tumors.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROTEASOME IN CANCER" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PROTEASOME IN CANCER" are provided by the European Opendata Portal: CORDIS opendata.